How Investors May Respond To Incyte (INCY) Expanding Opzelura’s Pediatric Use Following FDA Approval
In the past week, Incyte announced that the U.S. Food and Drug Administration approved Opzelura (ruxolitinib) cream for the treatment of mild to moderate atopic dermatitis in children as young as two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback